Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tretinoin + isotretinoin** is a combination of two retinoids, both derivatives of vitamin A, used individually to treat acne and certain skin conditions. Tretinoin (all-trans-retinoic acid) is typically used as a topical agent to promote skin cell turnover, treat acne, and reduce signs of photoaging; isotretinoin (13-cis-retinoic acid) is primarily an oral drug for severe, recalcitrant nodular or cystic acne that has not responded to other therapies. Both work by modulating gene expression, reducing sebum production, normalizing follicular keratinization, and exhibiting anti-inflammatory effects. While both are effective for various forms of acne, the combination is rarely used in clinical practice due to increased risk of additive toxicity, particularly hypervitaminosis A, and is generally not recommended unless under exceptional and closely monitored circumstances[3][4][8]. Limited studies have explored their combined use at low doses for difficult acne cases[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tretinoin + isotretinoin.